The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 18, 2012

Filed:

Mar. 15, 2010
Applicants:

Anatoly A. Mazurov, Greensboro, NC (US);

Lan Miao, Advance, NC (US);

Yun-de Xiao, Clemmons, NC (US);

Philip S. Hammond, Pinnacle, NC (US);

Craig H. Miller, Winston-Salem, NC (US);

Srinivisa Rao Akireddy, Winston-Salem, NC (US);

V. Srinivasa Murthy, Winston-Salem, NC (US);

Regina C. Whitaker, Mocksville, NC (US);

Scott R. Breining, Winston-Salem, NC (US);

Matt S. Melvin, Winston-Salem, NC (US);

Inventors:

Anatoly A. Mazurov, Greensboro, NC (US);

Lan Miao, Advance, NC (US);

Yun-De Xiao, Clemmons, NC (US);

Philip S. Hammond, Pinnacle, NC (US);

Craig H. Miller, Winston-Salem, NC (US);

Srinivisa Rao Akireddy, Winston-Salem, NC (US);

V. Srinivasa Murthy, Winston-Salem, NC (US);

Regina C. Whitaker, Mocksville, NC (US);

Scott R. Breining, Winston-Salem, NC (US);

Matt S. Melvin, Winston-Salem, NC (US);

Assignee:

Targacept, Inc., Winston-Salem, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 43/42 (2006.01); A01N 31/44 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).


Find Patent Forward Citations

Loading…